Cabio Biotech (China) Performance
| 688089 Stock | 18.03 0.06 0.33% |
The firm shows a Beta (market volatility) of 0.28, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cabio Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Cabio Biotech is expected to be smaller as well. Cabio Biotech Wuhan right now shows a risk of 4.19%. Please confirm Cabio Biotech Wuhan mean deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if Cabio Biotech Wuhan will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cabio Biotech Wuhan has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Cabio Biotech is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Payout Ratio 0.2941 | Last Split Factor 1.4:1 | Ex Dividend Date 2024-06-26 | Last Split Date 2023-07-18 |
1 | Nourish and CABIO partner to bring animal-free fat Tastilux to Chinese market - SmartCompany | 11/12/2024 |
2 | Cabio Biotech s earnings have declined over three years, contributing to shareholders 43 percent loss - Simply Wall St | 12/12/2024 |
| Begin Period Cash Flow | 490.6 M |
Cabio |
Cabio Biotech Relative Risk vs. Return Landscape
If you would invest 1,886 in Cabio Biotech Wuhan on October 11, 2024 and sell it today you would lose (83.00) from holding Cabio Biotech Wuhan or give up 4.4% of portfolio value over 90 days. Cabio Biotech Wuhan is generating 0.0139% of daily returns and assumes 4.1922% volatility on return distribution over the 90 days horizon. Simply put, 37% of stocks are less volatile than Cabio, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Cabio Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cabio Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cabio Biotech Wuhan, and traders can use it to determine the average amount a Cabio Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0033
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 688089 |
Estimated Market Risk
| 4.19 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cabio Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cabio Biotech by adding Cabio Biotech to a well-diversified portfolio.
Cabio Biotech Fundamentals Growth
Cabio Stock prices reflect investors' perceptions of the future prospects and financial health of Cabio Biotech, and Cabio Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cabio Stock performance.
| Return On Equity | 0.0733 | ||||
| Return On Asset | 0.0383 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 2.9 B | ||||
| Shares Outstanding | 168.31 M | ||||
| Price To Book | 1.99 X | ||||
| Price To Sales | 6.04 X | ||||
| Revenue | 443.8 M | ||||
| Gross Profit | 179.62 M | ||||
| EBITDA | 160.2 M | ||||
| Net Income | 91.37 M | ||||
| Total Debt | 12.1 M | ||||
| Book Value Per Share | 9.07 X | ||||
| Cash Flow From Operations | 68.89 M | ||||
| Earnings Per Share | 0.68 X | ||||
| Total Asset | 1.61 B | ||||
| Retained Earnings | 421.34 M | ||||
About Cabio Biotech Performance
By analyzing Cabio Biotech's fundamental ratios, stakeholders can gain valuable insights into Cabio Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cabio Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cabio Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cabio Biotech is entity of China. It is traded as Stock on SHG exchange.Things to note about Cabio Biotech Wuhan performance evaluation
Checking the ongoing alerts about Cabio Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cabio Biotech Wuhan help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cabio Biotech Wuhan had very high historical volatility over the last 90 days | |
| About 51.0% of the company shares are owned by insiders or employees | |
| Latest headline from news.google.com: Cabio Biotech s earnings have declined over three years, contributing to shareholders 43 percent loss - Simply Wall St |
- Analyzing Cabio Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cabio Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Cabio Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cabio Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cabio Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cabio Biotech's stock. These opinions can provide insight into Cabio Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cabio Stock analysis
When running Cabio Biotech's price analysis, check to measure Cabio Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cabio Biotech is operating at the current time. Most of Cabio Biotech's value examination focuses on studying past and present price action to predict the probability of Cabio Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cabio Biotech's price. Additionally, you may evaluate how the addition of Cabio Biotech to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |